Bendamustine-based chemotherapy induces high CR rate in relapsed HLJuly 8, 2016Indolent LymphomaAggressive Lymphomas
Adding obinutuzumab to bendamustine boosts progression-free survival in rituximab-refractory indolent non-Hodgkin lymphomaJune 28, 2016Indolent Lymphoma
Follicular lymphoma with histologic transformation may merit ASCTJune 14, 2016Indolent LymphomaAggressive Lymphomas
Epstein-Barr virus DNA in plasma reliably detects EBV-positive lymphoproliferative disordersMay 11, 2016Indolent LymphomaAggressive Lymphomas
Low transformation rate in nodular lymphocyte–predominant Hodgkin lymphomaApril 28, 2016Indolent Lymphoma
FDG-PET guides need for eBEACOPP in advanced Hodgkin’sApril 12, 2016Indolent LymphomaAggressive Lymphomas
CUDC-907 enters phase II for relapsed or refractory lymphoma and multiple myelomaApril 12, 2016Indolent Lymphoma
OTX015 dose for lymphoma narrowed in phase 1 studyApril 10, 2016Indolent LymphomaAggressive Lymphomas
